LicianPro

Anbio Biotechnology Class A Ordinary Shares

AAPL vs MSFT

Anbio Biotechnology Class A Ordinary Shares (NNNN) SEC filings

Anbio Biotechnology Class A Ordinary Shares (NNNN) SEC filings — 10-K, 10-Q, 8-K, and Form 4 as cached from EDGAR. When an exhibit lands, this page shows the headline, the numbers, and why it matters.

Those exhibit numbers sit next to the income-statement cache: Latest reported NNNN revenue for 2025-12-31 was $8.6M. Net income was $6.4M. Revenue was up 5.6% from 2024-12-31 to 2025-12-31. The NNNN filings page is the source view; the stock page is the research view.

EDGAR remains the official archive. Lician caches 8-K exhibits so you can read what Anbio Biotechnology Class A Ordinary Shares said without waiting on a live EDGAR scrape. Item 2.02 is the earnings exhibit — this page prefers EX-99.1 revenue, growth, EPS, and guidance over a form-type label. Form 4 insider prints stay on the same ticker timeline.

Earnings & events

All events

Event insights for NNNN — what management said, what changed, and why it matters.

No cached SEC filings for NNNN yet. When an 8-K lands, this page will list it.

These filings as JSON? API free 100/day

NNNN SEC filings FAQ

What events are listed on the NNNN SEC page?

Cached event headlines on this Anbio Biotechnology Class A Ordinary Shares (NNNN) SEC page: "NNNN earnings". Events: https://lician.com/sec/nnnn

What are NNNN's latest revenue and net income?

Latest cached Anbio Biotechnology Class A Ordinary Shares (NNNN) revenue for Dec 31, 2025 was $8.6M. Net income was $6.4M. Statements: https://lician.com/financials/nnnn